Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.

[1]  A. Sahebkar,et al.  Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta‐analysis of clinical trials , 2015, Diabetes, obesity & metabolism.

[2]  Hong Zhou,et al.  Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats. , 2015, European journal of pharmacology.

[3]  W. Ni,et al.  Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. , 2015, European journal of pharmacology.

[4]  M. Maa,et al.  Berberine reduces Toll-like receptor-mediated macrophage migration by suppression of Src enhancement. , 2015, European journal of pharmacology.

[5]  Xiao Wang,et al.  Berberine Suppresses Adipocyte Differentiation via Decreasing CREB Transcriptional Activity , 2015, PloS one.

[6]  Lin Zhao,et al.  Protective effect of berberine against myocardial ischemia reperfusion injury: role of Notch1/Hes1-PTEN/Akt signaling , 2015, Apoptosis.

[7]  Tongsheng Chen,et al.  Berberine Nanosuspension Enhances Hypoglycemic Efficacy on Streptozotocin Induced Diabetic C57BL/6 Mice , 2015, Evidence-based complementary and alternative medicine : eCAM.

[8]  Jun Wang,et al.  Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway , 2015, Journal of Translational Medicine.

[9]  D. Richardson,et al.  Adenosine Monophosphate–Activated Kinase and Its Key Role in Catabolism: Structure, Regulation, Biological Activity, and Pharmacological Activation , 2015, Molecular Pharmacology.

[10]  F. Di Pierro,et al.  Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins , 2015, Diabetes, metabolic syndrome and obesity : targets and therapy.

[11]  Ling Li,et al.  Effects of Berberine on Amelioration of Hyperglycemia and Oxidative Stress in High Glucose and High Fat Diet-Induced Diabetic Hamsters In Vivo , 2015, BioMed research international.

[12]  E. Favari,et al.  The natural compound berberine positively affects macrophage functions involved in atherogenesis. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[13]  F. Lu,et al.  Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia , 2015, Chinese Journal of Integrative Medicine.

[14]  Hanming Cui,et al.  In vitro studies of berberine metabolism and its effect of enzyme induction on HepG2 cells. , 2014, Journal of ethnopharmacology.

[15]  Yinggang Sun,et al.  Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE−/− mice , 2014, Journal of Translational Medicine.

[16]  G. Ning,et al.  Berberine activates thermogenesis in white and brown adipose tissue , 2014, Nature Communications.

[17]  Guoyin Wang,et al.  Berberine protects endothelial progenitor cell from damage of TNF-α via the PI3K/AKT/eNOS signaling pathway. , 2014, European journal of pharmacology.

[18]  Wei-Jia Kong,et al.  Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation. , 2014, Biological & pharmaceutical bulletin.

[19]  I. Song,et al.  Organic cation transporter-mediated drug–drug interaction potential between berberine and metformin , 2014, Archives of Pharmacal Research.

[20]  Yanwen Wang,et al.  Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. , 2014, Metabolism: clinical and experimental.

[21]  N. Tzemos,et al.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology? , 2014, World journal of cardiology.

[22]  Limei Liu,et al.  Uncoupling protein‐2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS‐1E cells and in diabetic mouse islets , 2014, British journal of pharmacology.

[23]  Chen Li,et al.  Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. , 2014, International journal of pharmaceutics.

[24]  Chen-Yu Zhang,et al.  Intestinal absorption of berberine and 8-hydroxy dihydroberberine and their effects on sugar absorption in rat small intestine , 2014, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[25]  F. Gao,et al.  Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K–Akt signaling in diabetic rats , 2014, Apoptosis.

[26]  N. Seidah,et al.  PCSK9: A Key Modulator of Cardiovascular Health , 2014, Circulation research.

[27]  Jian-Dong Jiang,et al.  Antioxidant and Anti-Inflammatory Activities of Berberine in the Treatment of Diabetes Mellitus , 2014, Evidence-based complementary and alternative medicine : eCAM.

[28]  Ling Wang,et al.  The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice. , 2014, Antioxidants & redox signaling.

[29]  D. Colombo,et al.  Cyclosporine and Herbal Supplement Interactions , 2014, Journal of toxicology.

[30]  Jing Li,et al.  Berberine Protects against Palmitate-Induced Endothelial Dysfunction: Involvements of Upregulation of AMPK and eNOS and Downregulation of NOX4 , 2013, Mediators of inflammation.

[31]  Shu-yu Yang,et al.  Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles , 2013, International journal of nanomedicine.

[32]  G. Marchesini,et al.  Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes , 2013, Clinical pharmacology : advances and applications.

[33]  Min Huang,et al.  Tissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats , 2013, PloS one.

[34]  A. D'Angelo,et al.  Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients , 2013, Expert opinion on biological therapy.

[35]  T. Kern,et al.  Leukocytes from diabetic patients kill retinal endothelial cells: Effects of berberine , 2013, Molecular vision.

[36]  E. Martínez-Abundis,et al.  Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. , 2013, Metabolic syndrome and related disorders.

[37]  Shijie Cao,et al.  Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells. , 2013, Journal of ethnopharmacology.

[38]  Jing Li,et al.  Berberine improves insulin resistance in cardiomyocytes via activation of 5'-adenosine monophosphate-activated protein kinase. , 2013, Metabolism: clinical and experimental.

[39]  Ye Zhang,et al.  Effects of β-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate. , 2013, International journal of biological macromolecules.

[40]  G. Derosa,et al.  Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. , 2013, Journal of biological regulators and homeostatic agents.

[41]  Xiaobing Fu,et al.  Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome , 2013, European Journal of Clinical Pharmacology.

[42]  C. Borghi,et al.  Combined nutraceutical approach to postmenopausal syndrome and vascular remodeling biomarkers. , 2013, Journal of alternative and complementary medicine.

[43]  Hong-Guang Xie,et al.  Berberine Ameliorates Chronic Kidney Injury Caused by Atherosclerotic Renovascular Disease through the Suppression of NFκB Signaling Pathway in Rats , 2013, PloS one.

[44]  Qin Wu,et al.  Effect of Berberine on PPARα/NO Activation in High Glucose- and Insulin-Induced Cardiomyocyte Hypertrophy , 2013, Evidence-based complementary and alternative medicine : eCAM.

[45]  F. Lu,et al.  The Effects of Berberine on Blood Lipids: A Systemic Review and Meta-Analysis of Randomized Controlled Trials , 2013, Planta Medica.

[46]  A. D'Angelo,et al.  Effects of berberine on lipid profile in subjects with low cardiovascular risk , 2013, Expert opinion on biological therapy.

[47]  Wei-Jia Kong,et al.  Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux. , 2013, Metabolism: clinical and experimental.

[48]  Joo-Yong Lee,et al.  Inhibitory effects of berberine on lipopolysaccharide-induced inducible nitric oxide synthase and the high-mobility group box 1 release in macrophages. , 2013, Biochemical and biophysical research communications.

[49]  Dan Tang,et al.  Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochloride , 2013, Drug development and industrial pharmacy.

[50]  Z. Shen,et al.  Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell. , 2012, European journal of pharmacology.

[51]  Jing Li,et al.  Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis , 2012, Molecular and Cellular Endocrinology.

[52]  F. Lu,et al.  Berberine in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis , 2012, Evidence-based complementary and alternative medicine : eCAM.

[53]  Ranjeet P. Dash,et al.  Simultaneous quantification of berberine and lysergol by HPLC-UV: evidence that lysergol enhances the oral bioavailability of berberine in rats. , 2012, Biomedical chromatography : BMC.

[54]  Anand Rahigude,et al.  Possible therapeutic potential of berberine in diabetic osteopathy. , 2012, Medical hypotheses.

[55]  Gao Fy,et al.  A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats. , 2012 .

[56]  S. Bertolini,et al.  Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment , 2012, Lipids in Health and Disease.

[57]  M. Li,et al.  Structural Changes of Gut Microbiota during Berberine-Mediated Prevention of Obesity and Insulin Resistance in High-Fat Diet-Fed Rats , 2012, PloS one.

[58]  G. Marchesini,et al.  Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control , 2012, Diabetes, metabolic syndrome and obesity : targets and therapy.

[59]  Xin Gao,et al.  The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet , 2012, Lipids in Health and Disease.

[60]  Hong-Bo Xiao,et al.  Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation , 2012, Pharmacological reports : PR.

[61]  Ying-Ju Lai,et al.  Berberine Reduces Leukocyte Adhesion to Lps-Stimulated Endothelial Cells and Vcam-1 Expression Both In Vivo and In Vitro , 2012, International journal of immunopathology and pharmacology.

[62]  V. Mercurio,et al.  A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. , 2012, World journal of cardiology.

[63]  Kevin Y. Yip,et al.  Sustained Antidiabetic Effects of a Berberine-Containing Chinese Herbal Medicine Through Regulation of Hepatic Gene Expression , 2012, Diabetes.

[64]  Yan Wang,et al.  Berberine Improves Insulin Sensitivity by Inhibiting Fat Store and Adjusting Adipokines Profile in Human Preadipocytes and Metabolic Syndrome Patients , 2012, Evidence-based complementary and alternative medicine : eCAM.

[65]  Jin-Yuarn Lin,et al.  Protective effect of berberine on serum glucose levels in non-obese diabetic mice. , 2012, International immunopharmacology.

[66]  B. Viollet,et al.  AMP-activated protein kinase pathway and bone metabolism. , 2012, The Journal of endocrinology.

[67]  G. Lastra,et al.  Over-nutrition, obesity and insulin resistance in the development of β-cell dysfunction. , 2012, Current diabetes reviews.

[68]  Shu Meng,et al.  Suppression of oxLDL‐Induced MMP‐9 and EMMPRIN Expression by Berberine via Inhibition of NF‐κB Activation in Human THP‐1 Macrophages , 2012, Anatomical record.

[69]  Xing Tang,et al.  Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine in rats , 2012, Drug development and industrial pharmacy.

[70]  F. Pelliccia,et al.  Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients , 2011, Advances in therapy.

[71]  Qilong Wang,et al.  Activation of AMP-Activated Protein Kinase Is Required for Berberine-Induced Reduction of Atherosclerosis in Mice: The Role of Uncoupling Protein 2 , 2011, PloS one.

[72]  Jianan Wang,et al.  Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[73]  W. Xie,et al.  Effects and Action Mechanisms of Berberine and Rhizoma coptidis on Gut Microbes and Obesity in High-Fat Diet-Fed C57BL/6J Mice , 2011, PloS one.

[74]  C. Klaassen,et al.  Repeated administration of berberine inhibits cytochromes P450 in humans , 2011, European Journal of Clinical Pharmacology.

[75]  Jin-Yuarn Lin,et al.  Berberine, an isoquinoline alkaloid in herbal plants, protects pancreatic islets and serum lipids in nonobese diabetic mice. , 2011, Journal of agricultural and food chemistry.

[76]  Jian-ning Sun,et al.  Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. , 2011, European journal of pharmacology.

[77]  Junling Han,et al.  Modulating gut microbiota as an anti-diabetic mechanism of berberine , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[78]  Xing Tang,et al.  Bioavailability Study of Berberine and the Enhancing Effects of TPGS on Intestinal Absorption in Rats , 2011, AAPS PharmSciTech.

[79]  G. Ning,et al.  Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes. , 2011, Biochimica et biophysica acta.

[80]  Jianping Ye,et al.  Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis , 2011, PloS one.

[81]  Shu Meng,et al.  Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. , 2011, International journal of cardiology.

[82]  C. Ting,et al.  Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells. , 2011, European journal of pharmacology.

[83]  L. Saccá,et al.  Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[84]  Hong-Guang Xie,et al.  Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats , 2010, Drug Metabolism and Disposition.

[85]  Xinhua Xiao,et al.  Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism , 2010, Evidence-based complementary and alternative medicine : eCAM.

[86]  S. Shyue,et al.  Anti‐atherogenic effect of berberine on LXRα‐ABCA1‐dependent cholesterol efflux in macrophages , 2010, Journal of cellular biochemistry.

[87]  M. Gu,et al.  8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. , 2010, Bioorganic & medicinal chemistry.

[88]  G. Davies,et al.  Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. , 2010, Fitoterapia.

[89]  Shu-Hua Tai,et al.  A systematic review and meta‐analysis on the therapeutic equivalence of statins , 2010, Journal of clinical pharmacy and therapeutics.

[90]  Jing Li,et al.  Enhancement of Sodium Caprate on Intestine Absorption and Antidiabetic Action of Berberine , 2010, AAPS PharmSciTech.

[91]  Y. Siow,et al.  Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages. , 2010, Canadian journal of physiology and pharmacology.

[92]  Wei-Jia Kong,et al.  Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. , 2010, Metabolism: clinical and experimental.

[93]  Guangji Wang,et al.  Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. , 2009, Journal of pharmaceutical sciences.

[94]  G. Davies,et al.  Berberine increases expression of GATA-2 and GATA-3 during inhibition of adipocyte differentiation. , 2009, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[95]  Jingwen Liu,et al.  Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine* , 2009, The Journal of Biological Chemistry.

[96]  A. Xu,et al.  Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. , 2009, Cardiovascular research.

[97]  T. Han,et al.  Effects of berberine on differentiation and bone resorption of osteoclasts derived from rat bone marrow cells. , 2009, Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine.

[98]  J. B. Kim,et al.  Berberine suppresses proinflammatory responses through AMPK activation in macrophages. , 2009, American journal of physiology. Endocrinology and metabolism.

[99]  M. Lane,et al.  Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. , 2009, American journal of physiology. Endocrinology and metabolism.

[100]  Y. Liu,et al.  Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy. , 2009, Journal of medicinal chemistry.

[101]  Peiqing Liu,et al.  Berberine reduces fibronectin and collagen accumulation in rat glomerular mesangial cells cultured under high glucose condition , 2009, Molecular and Cellular Biochemistry.

[102]  T. Ranheim,et al.  Berberine decreases PCSK9 expression in HepG2 cells. , 2008, Atherosclerosis.

[103]  Guangji Wang,et al.  Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. , 2008, The Journal of endocrinology.

[104]  F. Qiu,et al.  Short Communication Isolation and Identification of Urinary Metabolites of Berberine in Rats and Humans , 2008 .

[105]  Jiemei Wang,et al.  Berberine-Induced Upregulation of Circulating Endothelial Progenitor Cells Is Related to Nitric Oxide Production in Healthy Subjects , 2008, Cardiology.

[106]  Wei-Jia Kong,et al.  Combination of simvastatin with berberine improves the lipid-lowering efficacy. , 2008, Metabolism: clinical and experimental.

[107]  H. Hosseinzadeh,et al.  Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine , 2008, Phytotherapy research : PTR.

[108]  Je-Yong Choi,et al.  Berberine Promotes Osteoblast Differentiation by Runx2 Activation With p38 MAPK , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[109]  Shufeng Zhou,et al.  Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. , 2008, Archives of biochemistry and biophysics.

[110]  P. Dy,et al.  Preparation and evaluation of a microemulsion for oral delivery of berberine. , 2008, Die Pharmazie.

[111]  Z. Yang,et al.  Berberine-induced mobilization of circulating endothelial progenitor cells improves human small artery elasticity , 2008, Journal of Human Hypertension.

[112]  Jianping Ye,et al.  Efficacy of berberine in patients with type 2 diabetes mellitus. , 2008, Metabolism: clinical and experimental.

[113]  D. James,et al.  Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I , 2008, Diabetes.

[114]  Hyun-Joung Lim,et al.  Berberine-induced LDLR up-regulation involves JNK pathway. , 2007, Biochemical and biophysical research communications.

[115]  C. Hyun,et al.  Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes. , 2007, Biological & pharmaceutical bulletin.

[116]  L. Ding,et al.  Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. , 2007, Journal of pharmaceutical and biomedical analysis.

[117]  Jung-Ae Kim,et al.  Inhibitory effects of Zoagumhwan water extract and berberine on angiotensin II-induced monocyte chemoattractant protein (MCP)-1 expression and monocyte adhesion to endothelial cells. , 2007, Vascular pharmacology.

[118]  K. Ueda,et al.  Human MDR1 and MRP1 Recognize Berberine as Their Transport Substrate , 2007, Bioscience, biotechnology, and biochemistry.

[119]  Ji-won Park,et al.  Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte , 2006, Experimental & Molecular Medicine.

[120]  R. Paltriccia,et al.  Increased Ratio of CD31+/CD42− Microparticles to Endothelial Progenitors as a Novel Marker of Atherosclerosis in Hypercholesterolemia , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[121]  Yuebo Zhang,et al.  Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway , 2006 .

[122]  D. James,et al.  Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States , 2006, Diabetes.

[123]  J. Brusq,et al.  Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine Published, JLR Papers in Press, February 28, 2006. , 2006, Journal of Lipid Research.

[124]  Hyun-Joung Lim,et al.  Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. , 2006, Atherosclerosis.

[125]  Y. Jang,et al.  Berberine inhibits the production of lysophosphatidylcholine-induced reactive oxygen species and the ERK1/2 pathway in vascular smooth muscle cells. , 2005, Molecules and cells.

[126]  Satoru Inaba,et al.  Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins , 2004, Nature Medicine.

[127]  F. Lu,et al.  Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. , 2004, Acta pharmacologica Sinica.

[128]  J. P. Fawcett,et al.  The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. , 2003, Planta medica.

[129]  C. Shim,et al.  P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. , 2002, Journal of pharmaceutical sciences.

[130]  J. P. Fawcett,et al.  The involvement of P-glycoprotein in berberine absorption. , 2002, Pharmacology & toxicology.

[131]  R. Tisch,et al.  Insulin-Dependent Diabetes Mellitus , 1996, Cell.

[132]  Wei Li,et al.  Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. , 2010, The American journal of Chinese medicine.

[133]  Wei-Jia Kong,et al.  Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. , 2009, Metabolism: clinical and experimental.

[134]  Jianping Ye,et al.  Berberine improves glucose metabolism through induction of glycolysis. , 2008, American journal of physiology. Endocrinology and metabolism.